Share this article

Eli Lilly is set to invest $400m to boost the capacity of its manufacturing facilities at its technology centre campus in Indianapolis, Indiana, US.

The move is intended to meet the increasing demand for the company’s existing medicines and to support the production of future drugs in its pipeline.

Lilly will use the capital to add enhancements to facilities that manufacture insulin, boost capacity for its diabetes portfolio and as initial capital for future drugs.

Furthermore, the company expects the investment to create nearly 100 jobs in manufacturing.

Eli Lilly chairman and CEO David Ricks said: “These investments demonstrate Lilly’s commitment to our manufacturing footprint in Indiana and the US and have been made possible by the tax reform measures passed by Congress in 2017.

“With more capital available as a result of tax reform, Lilly and other Indiana companies are able to re-invest and expand production here at home.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

The investment will bring capacity and technology upgrades to the company’s active ingredient, syringe filling, device assembly and packaging operations.

The company’s senior vice-president and president of manufacturing operations Myles O’Neill said: “All of these projects support Lilly’s investment in next generation manufacturing and feature high levels of automation, robotics, new technologies and advanced data analytics.”

Founded in 1876, Lilly develops medicines across a variety of therapeutic areas, including oncology, cardiovascular, diabetes, immunology and neuroscience.

Since 2012, the company has invested more than $5bn in the US, with the majority for Indiana facilities and around $2bn to manufacture diabetes medicines.